Xcout Intel
Verona Pharma
Verona Pharma plc focuses on innovative respiratory treatments and is headquartered in London, UK, alongside offices in the United States.
Subscribe to see Verona Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Verona Pharma at a glance
Verona Pharma is a pharmaceuticals company headquartered in United Kingdom, founded in 2005. It has raised at least $1B across the 4 funding rounds on record. Its most recent funding round, Private Placement, raised $650M in May 2024.
Verona Pharma funding rounds
At least $1B raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Private Placement | $650M | 14 named | |
| SEC Form D filing | $200.2M | — | |
| — | $200.2M | — | |
| SEC Form D filing | $44.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Verona Pharma news
Investors
Verona Pharma competitors
A few of Verona Pharma's closest competitors — see the full list of competitors and alternatives →
Chiesi Farmaceutici is a global biopharmaceutical group that researches, develops, and commercializes therapeutic solutions for patients. The company focuses primarily on respiratory health, rare diseases, and specialty care.
Hudson Pharma is a branded generic pharmaceutical company that develops and manufactures treatments across segments such as respiratory, injectables, ophthalmic, and dermatology. The company serves doctors and patients globally by providing affordable, first-line therapies for conditions ranging from asthma and glaucoma to infections and vitamin deficiencies.
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Botanix Pharmaceuticals Ltd. is a dermatology company focused on developing pharmaceutical products and treatments. The company is headquartered in West Perth, Western Australia, and operates within the Australian life sciences market.
Almirall is a Spanish pharmaceutical company headquartered in Barcelona, focused primarily on researching, developing, and commercializing prescription medicines for dermatological diseases, with additional activities in areas such as respiratory health. It serves patients and healthcare professionals through products marketed in Spain and international markets.
Get Verona Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Verona Pharma in Xcout Intel
- 4 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access